Do you want to read an article? Please log in or register.
Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
Lancet Gastroenterol Hepatol
Reinisch W, Stepek D, Kempinski R, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Jairath V
doi: 10.1016/S2468-1253(26)00120-2
RECOMMENDED
Further Publications
Ustekinumab for fistulising perianal Crohn's disease: a randomised placebo-controlled trial from the GETAID
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Gut
Wils P, Nancey S, Messmer E, Bourreille A, Buisson A, Caillo L, Vuitton L, Altwegg R, Hébuterne X, Ernst O, Meunier P, Laurent V, Paul S, Laharie D, Vicaut E, Peyrin-Biroulet L, Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
doi: 10.1136/gutjnl-2026-339158
Inflammatory Bowel Disease
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial
Inflamm Bowel Dis
Afzali A, Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, Panés J, Van Rampelbergh R, Terry NA, Salese L, Vetter ML, Yee J, Corbett C, van Duijnhoven W, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI 1 investigators
doi: 10.1093/ibd/izag055
Inflammatory Bowel Disease
Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial
Clin Gastroenterol Hepatol
Sands BE, Barnes EL, D'Haens G, Hisamatsu T, Regueiro M, Kelly CR, Laharie D, Hozak RR, Yu G, Gandhi R A, Lopes MU, Durand F, Protic M, Moses RE, Vermeire S
doi: 10.1016/j.cgh.2026.01.049
Inflammatory Bowel Disease
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol
Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group
doi: 10.1016/S2468-1253(25)00322-X
Inflammatory Bowel Disease
Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study
J Crohns Colitis
Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK
doi: 10.1093/ecco-jcc/jjaf213
Inflammatory Bowel Disease
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial
J Crohns Colitis
Raine T, Danese S, Schreiber S, Gao X, Hanauer S, Torres J, Cunneen C, Kligys K, Huang X, Garrison A, Neimark E, Anschutz T, Crowley J, Cross RK
doi: 10.1093/ecco-jcc/jjag104
Inflammatory Bowel Disease
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis
Adv Ther
Schreiber S, Danese S, Colombel JF, Hisamatsu T, Irving PM, Park H, Kim DH, Lee YN, Hanauer SB
doi: 10.1007/s12325-025-03447-6
Inflammatory Bowel Disease
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg
J Crohns Colitis
De Greef E, Turner D, Kierkuś J, Korczowski B, Meglicka M, Cohen SA, Hyams JS, Griffiths AM, Rosh JR, Strauss R, Van Limbergen E, Adedokun OJ, Kim L, Volger S, UNITI Jr study Group
doi: 10.1093/ecco-jcc/jjag011